News

Contact this office:
812-877-8442

NEWS: On Campus

< Back to On Campus
< Back to all News

Cutting-Edge Cancer Scientist Dr. Bruce Horten to Discuss Revolutionary Therapy Techniques in Nov. 29 Signature Lecture

November 26, 2012

Bruce Horten 2  
Dr. Bruce Horten, cancer researcher,
comes to campus.
 

Cutting-Edge Cancer Scientist Dr. Bruce Horten to Discuss Revolutionary Therapy Techniques in Nov. 29 Signature Lecture

Leading cancer scientist Bruce Horten, M.D., will highlight his cutting edge techniques of engineering new cancer treatments in a presentation on Thursday, November 29, at Rose-Hulman Institute of Technology's Hatfield Hall Theater, starting at 7 p.m. The event is free and open to the public.

Horton's presentation, "Targets: Transforming the Assault on Cancer," will cover a revolutionary cancer therapy that's based on a patient's genetic makeup. He is one of the world's leading experts in classifying and targeting specific cancers using Fluorescent in Situ Hybridization (FISH) to literally "FISH" for chromosomal abnormalities-deletions in DNA that can cause cancer.

By studying these abnormalities, Horten and others have become more adept at identifying specific forms of cancer and targeting drugs that are disease specific to weaken the cancer without also weakening the health of the individual cancer patient.

The science of pathogenesis -- investigating the genetic variations underlying tumor development and progression -- has progressed from simply classifying cancers to predictive analysis and therapy.

"In the 21st Century, the entire approach to cancer therapy has changed-especially the cancer drugs-from poisoning the patient with the hope that you will poison the cancer more than the patient, to finding drugs that are relatively harmless to the patient, but toxic to the cancer," stated Horten.

As National Medical Director for the Integrated Oncology laboratory at LabCorp (formerly Genzyme Genetics) since 2004, Horten oversees the strategic development of the company's oncology business and spearheads educational initiatives concerning cancer-related issues. He also has been medical director of IMPATH's Eastern Division, and served on the pathology staffs of the Memorial Sloan-Kettering Cancer Center, the University of California at San Francisco, and Lenox Hill Hospital. to new ownership.

  Dr. Bruce Horten
   

Engineering better medicines is one of the Grand Challenges of Engineering, as identified by the National Academy of Engineering. One area of interest is having engineers develop new systems to use genetic information, sense small changes in the body, assess new drugs, and deliver drugs to address medical conditions.

This is why Rose-Hulman is bringing Horten to speak to its students, faculty and staff members at the Signature Lecture Series event, according to William Kline, Ph.D., Rose-Hulman's Dean of Innovation and Engagement. Horten also conducted an interactive Internet video conference with Rose-Hulman students to preview topics being discussed in his upcoming presentation.

"Engineers are becoming ever more important in the field of medicine," Kline acknowledged. "Biotechnologists, computer and software engineers, and chemical engineers are just a few of the specialties involved in helping medical doctors make these astounding breakthroughs."